“Guess what!? We’re in Raleigh/Durham for the State of the Science Summit on Hematologic Malignancies with @DukeCancer — going to be a fantastic night ahead!” tweeted OncLive, the official website for the Oncology Specialty Group whose mission it is to provide resources and information oncology professionals need to deliver the best patient care.
OncLive partnered with the Duke Division of Hematologic Malignancies and Cellular Therapy to host the educational summit in Durham on Wednesday night, May 1, featuring 15-minute presentations by Duke Cancer Institute blood cancer specialists Danielle Brander, MD; Nelson Chao, MD; Carlos DeCastro, MD; Harry Erba, MD; Ahmed Galal, MD; Yubin Kang, MD; Thomas LeBlanc, MD; Matthew McKinney, MD; Lindsay Rein, MD; Cristina Gasparetto, MD; and David Rizzieri, MD.
Gasparetto and Erba co-chaired the special event, held at the DoubleTree Hilton Raleigh Durham Airport hotel, which drew about 50 oncologists, fellows, nurse practitioners, nurses, and physician assistants from Duke and the community.
They learned about new scientific discoveries and novel treatment approaches in follicular lymphoma, Hodgkin's and non-Hodgkin's lymphoma, mantle cell lymphoma, acute and chronic myeloid leukemia (AML & CML), chronic and acute lymphocytic leukemia (ALL & CLL), multiple myeloma, severe aplastic anemia, and CAR-T cell therapy.
"The summit highlighted the breadth and depth of knowledge and clinical experience of our faculty," said Erba, who directs the Leukemia Program and Phase I Development in Hematologic Malignancies at Duke Cancer Institute. "Many from our own teams including nurses and advanced practice providers took time from their own personal lives to join us and learn more about the diseases we treat."
OncLive conducted several one-on-one interviews during the summit, which were featured in the days following the event OncLive website. Here are some of them below:
Photos courtesy of OncLive SOSS Twitter